Selective Estrogen Receptor Down Regulator
Roche Claims Its SERD Is Most Potent After Positive Breast Cancer Data Presented at ESMO 2025
Roche; SERD; giredestrant; breast cancer; ESMO 2025; progression-free survival; oral SERD; ER-positive; HER2-negative; phase 3 trial